|

SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

RECRUITINGPhase 1Sponsored by The Affiliated Hospital of Qingdao University
Actively Recruiting
PhasePhase 1
SponsorThe Affiliated Hospital of Qingdao University
Started2023-08-02
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06544720

Summary

A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Key Inclusion Criteria:

1. Greater than or equal to 18 years of age
2. HPV associated carcinomas
3. Patients must have at least one measurable lesion defined by RECIST 1.1
4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Key Exclusion Criteria:

1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.
2. Patients with active autoimmune diseases.
3. Patient has a known active Hepatitis B or Hepatitis C.
4. Other severe medical conditions that may limit subject\'s participation in this trial.

Conditions9

Anal CancerCancerCervical CancerHPV-Related MalignancyHead and Neck CancersHuman Papillomavirus Associated CarcinomasPenile CancerVaginal CancerVulva Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.